



Altimune to Participate in Upcoming Investor Conferences

March 2, 2026 at 7:30 AM EST

GAITHERSBURG, Md., March 02, 2026 (GLOBE NEWSWIRE) -- [Altimune, Inc.](#) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:

- **Leerink Global Healthcare Conference**
Monday, March 9, 2026 – *One-on-one meetings*
Wednesday, March 11, 2026 – *Fireside chat at 9:20 a.m. ET*
- **Citizens Life Sciences Conference**
Tuesday, March 10, 2026 – *One-on-one meetings*
Fireside chat at 2:15 p.m. ET
- **Jefferies Biotech on the Beach Summit**
Wednesday, March 11, 2026 – *One-on-one meetings only*
- **Barclays 28th Annual Global Healthcare Conference**
Thursday, March 12, 2026 – *One-on-one meetings*
Fireside chat at 10:30 a.m. ET

Webcasts of the fireside chats at the Leerink, Citizens and Barclays conferences will be available via the [Events](#) section of the Altimune website.

Registered investors may request meetings on the dates noted above via their sales contacts at the respective banks.

About Altimune

Altimune is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's lead candidate, pemvidutide, is a unique dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD). For more information, please visit www.altimmune.com.

Follow [@Altimune, Inc. on LinkedIn](#)

Follow [@AltimuneInc on X](#)

Investor Contact:

Lee Roth
Burns McClellan
lroth@burnsmc.com

Media Contact:

Real Chemistry
altimmune@realchemistry.com

This press release was published by a CLEAR® Verified individual.



Source: Altimune, Inc